A Study to Explore the Renal Safety of Visipaque Injection 320 mgI/mL in Patients With Chronic Kidney Disease
Status:
Terminated
Trial end date:
2018-10-19
Target enrollment:
Participant gender:
Summary
This parallel-group, randomized, placebo-controlled study will examine the incidence and
severity of acute kidney injury (AKI) in patients with chronic kidney disease (CKD) stage
III/IV following an i.v. injection of iso-osmolar iodinated contrast material iodixanol
(Visipaque™ Injection 320 mgI/mL), as compared with patients who received saline and
underwent a non-enhanced CT (NECT) and duplex ultrasound (US) during their scheduled
post-EVAR surveillance imaging.